Question-and-Answer Session
Operator
At this time we will take questions that you may have. (Operator Instructions). First question comes from Charles (Inaudible) of Prime Investments. Please proceed.
Unidentified Analyst
Thank you very much great job on the numbers out there gentlemen great job, looks great. Just a quick question on the ADL5945 the one you just picked up from your new liability. When do you guys think you are going to start actually putting that into clinical and what kind of a timeframe you are looking at to get it into stage one? Or through stage 1?
Mike Dougherty
Yeah this is Mike, thanks for that question and may be I'll start and ask Eliseo to make any supplemental comments as you may know really actually prior to our in license had done some work on this compound and the different indication and with that had done some Phase 1 work. So our expectation is to very quickly and soon do some additional Phase 1 work, but more importantly to them introduce this compound into some very early efficacy. Clinical evaluation and the unique opportunity here is to do that in parallel with our ADL7445 compound. So, we expect to have that Lilly compound in the clinic in 2010.
Eliseo Salinas
As Mike said, there are two interesting aspects of this program. One is that, to make it coincide with 7445 and run the same studies essentially with the two molecules. The second is that, as you know Adolor had an extensive experience in the area of OBD which is not easy. It's a very challenging area. You're talking about receptors that have been exposed to chronic opioid stimulation and you are given an antagonist which poses a number of pharmacology and clinical programs. Because of that experience, we think that we can accelerate this and be in a measure to get into the next phase by the end of 2010, including efficacy risk in both compounds.
Unidentified analyst
And just a quick follow up, question as far as the financials go. I know publicly you said you're going to end the year with right around $85 million something like that, plus or minus. Does that number still stand or did this throw it off a little bit as far as picking up this drug?
Eliseo Salinas
I think from an operating standpoint, the number is still good. That did not contemplate the $2 million payment to Lilly. So we do need to factor that into our earlier numbers that we did in conjunction with the restructuring.
- To read the full transcript on Seeking Alpha, click here »
